Nurix Therapeutics, Inc. (NRIX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$68.7M
Cash & Equivalents
$168.5M
Quarterly Burn Rate
1 mo
Est. Cash Runway
$2,385M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-08-31 | Phase1 Readout | — |
| 2027-01-01 | Phase1 Readout | — |
Active Clinical Trials (5)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07221500 | A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymp... | PHASE2 | Recruiting | 100 |
| NCT04830137 | A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | PHASE1 | Recruiting | 248 |
| NCT05107674 | A Study of NX-1607 in Adults With Advanced Malignancies | PHASE1 | Recruiting | 345 |
| NCT06717269 | Relative Bioavailability of NX-5948 Tablets vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets | PHASE1 | Recruiting | 18 |
| NCT05131022 | A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | PHASE1 | Recruiting | 572 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.